Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Fulgent Genetics, Inc.FLGT · healthcare | |
|---|---|
| Grade |  Dfourth fifth of 371 graded peers; percentile 65.1, sampling error 2.5 points; lower is stronger |
| Rank | 242 of 371 |
| Profitability | Epercentile 83.8 |
| Solvency | Apercentile 16.6 |
| Growth and financing | C/Dpercentile 59.2 |
| Reliability | 0.91 AUCfailure model, filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| Peer failure rate | 1.01% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $591M to $2.67B assetstotal assets $1.2B[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | short runwaynot computable: distress, fortress balance sheet |
| Inputs computable | 8 of 14 |
| Graded from | filings received through Feb 27, 2026224 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $20.872026-10-08; market equity $574.2M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Feb 27, 2026; the document on sec.gov.
We are a technology-based company with a well-established laboratory services business and a therapeutic development business. Our laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Our therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. Founded in 2011, Fulgent began with two simple ideas: flexibility and affordability.
Warnings [top]
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 83.8 | |||||||
| Gross profitability | 10.8% | [1,4] | 32.2% | 75.2 | 372 | 2025-12-31 | |
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | 3.4% | [1,5-7] | (6.6%) | 86.0 | 811 | 2025-12-31 | |
| Gross margin stability, five years | 16.2 pts | [2,4,8-15] | 2.8 pts | 90.1 | 243 | 2025-12-31 | |
| Solvency, sleeve percentile 16.6 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | 14.37 | [1,16-21] | (0.31) | 5.0 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31 | |||||||
| Current ratio | 6.48x | [16-17] | 2.96x | 28.2 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 59.2 | |||||||
| Revenue growth, three-year compound | (19.5%) | [2,9,11,13] | 10.0% | 88.9 | 415 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| NOPAT must exceed $100,000 | |||||||
| Asset growth, three years | (4.3%) | [1,7,22-23] | 2.1% | 61.6 | 704 | 2025-12-31 | |
| Net share issuance, one year | 1.3% | [24-25] | 2.5% | 27.0 | 634 | 2026-02-23 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite 0.071; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 237 | Royalty Pharma plc (RPRX) Royalty Pharma plc (RPRX) Dfourth fifth; percentile 63.8 Nasdaq · Pharmaceutical Preparations market equity $21.8B; last close $56.22 No active warnings; 7 of 14 inputs | 63.8 | D | |
| 238 | Integra Lifesciences Holdings Corp. (IART) Integra Lifesciences Holdings Corp. (IART) Dfourth fifth; percentile 64.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $1.0B; last close $13.43 No active warnings; 10 of 14 inputs | 64.1 | D | |
| 239 | Alpha Teknova, Inc. (TKNO) Alpha Teknova, Inc. (TKNO) Dfourth fifth; percentile 64.3 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $453.1M; last close $8.45 No active warnings; 9 of 14 inputs | 64.3 | D | |
| 240 | Arvinas, Inc. (ARVN) Arvinas, Inc. (ARVN) Dfourth fifth; percentile 64.6 Nasdaq · Pharmaceutical Preparations market equity $491.1M; last close $7.51 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | 64.6 | D | short runway, fortress balance sheet |
| 241 | Organogenesis Holdings Inc. (ORGO) Organogenesis Holdings Inc. (ORGO) Dfourth fifth; percentile 64.9 Nasdaq · Pharmaceutical Preparations market equity $164.7M; last close $1.27 Warnings: fortress balance sheet; 7 of 14 inputs | 64.9 | D | fortress balance sheet |
| 242 | Fulgent Genetics, Inc. (FLGT) Fulgent Genetics, Inc. (FLGT) Dfourth fifth; percentile 65.1 Nasdaq · Services-Medical Laboratories market equity $572.9M; last close $20.87 Warnings: short runway; 8 of 14 inputs | 65.1 | D | short runway |
| 243 | Entera Bio Ltd. (ENTX) Entera Bio Ltd. (ENTX) Dfourth fifth; percentile 65.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $432.9M; last close $2.51 Warnings: degenerate inputs; 7 of 14 inputs | 65.4 | D | degenerate inputs |
| 244 | Dentsply Sirona Inc. (XRAY) Dentsply Sirona Inc. (XRAY) Dfourth fifth; percentile 65.7 Nasdaq · Dental Equipment & Supplies market equity $1.7B; last close $8.68 No active warnings; 9 of 14 inputs | 65.7 | D | |
| 245 | InspireMD, Inc. (NSPR) InspireMD, Inc. (NSPR) Dfourth fifth; percentile 65.9 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $22.3M; last close $0.47 Warnings: dilution, short runway, distress; 9 of 14 inputs | 65.9 | D | dilution, short runway, distress |
| 246 | Angiodynamics Inc. (ANGO) Angiodynamics Inc. (ANGO) Dfourth fifth; percentile 66.2 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $472.3M; last close $11.22 Warnings: fortress balance sheet; 7 of 14 inputs | 66.2 | D | fortress balance sheet |
| 247 | AIM ImmunoTech Inc. (AIM) AIM ImmunoTech Inc. (AIM) Dfourth fifth; percentile 66.5 NYSE · Biological Products, (No Diagnostic Substances) market equity $5.5M; last close $0.18 Warnings: late filer, degenerate inputs, distress; 8 of 14 inputs | 66.5 | D | late filer, degenerate inputs, distress |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | D | 71.8 | 2204 |
| sector peers, equal sleeves (the grade) | D | 65.1 | 371 |
| same exchange, equal sleeves | D | 68.0 | 1219 |
| sector peers, equal inputs | D/E | 77.6 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (14.3%) | 8.0% | 36 | hotter than 36 of 100 peers |
| Distance from 52-week high | (32.5%) | (31.4%) | 47 | closer to its high than 47 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | (21.7%) | (1.0%) | 22 | pricier than 78 of 100 peers |
| Book value to price | 1.75 | 0.28 | 95 | pricier than 5 of 100 peers |
| Sales to price | 0.56 | 0.31 | 70 | pricier than 30 of 100 peers |
| Composite equity issuance, five years | (4.8%) | 20.3% | 20 | more equity-funded than 20 of 100 peers |
| Relative strength against the sector, log excess return | (0.37) | (0.14) | 36 | ahead of 36 of 100 peers |
Inputs: market equity $572.9M; EBIT -$91.1M; free cash flow -$124.2M; book equity $1.0B; sales $322.7M; cash $26.3M[26].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (5.0%) | ✗ fail[5,7] |
| Operating cash flow above zero | -$101.6M | ✗ fail[6] |
| Return on assets improved | (1.5 pts) | ✗ fail[5,7,22,27] |
| Operating cash flow exceeds net income | -$41.1M | ✗ fail[5-6] |
| Long-term leverage fell | n/a[1,7,22] | |
| Current ratio improved | 162.9 pts | ✓ pass[16-17,28-29] |
| No new shares issued | 1.3% | ✗ fail[24-25] |
| Gross margin improved | 2.7 pts | ✓ pass[2,4,8-9] |
| Asset turnover improved | 3.5 pts | ✓ pass[2,7,9,22] |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $1.2B | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $322.7M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $26.3M | 2026-06-30 | 2026-07-30 | 10-Q | filing · viewer · series |
| 4 | gross profit | us-gaap:GrossProfit | $130.9M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 5 | net income | us-gaap:NetIncomeLoss | -$60.5M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 6 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$101.6M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 7 | assets | us-gaap:Assets | $1.2B | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 8 | gross profit | us-gaap:GrossProfit | $107.2M | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 9 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $283.5M | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 10 | gross profit | us-gaap:GrossProfit | $104.5M | 2023-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $289.2M | 2023-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 12 | gross profit | us-gaap:GrossProfit | $366.9M | 2022-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $619.0M | 2022-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 14 | gross profit | us-gaap:GrossProfit | $777.1M | 2021-12-31 | 2024-02-28 | 10-K | filing · viewer · series |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $992.6M | 2021-12-31 | 2024-02-28 | 10-K | filing · viewer · series |
| 16 | current assets | us-gaap:AssetsCurrent | $550.5M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 17 | current liabilities | us-gaap:LiabilitiesCurrent | $85.0M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 18 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $530.0M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 19 | operating income | us-gaap:OperatingIncomeLoss | -$91.1M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 20 | book equity | us-gaap:StockholdersEquity | $1.1B | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 21 | liabilities | us-gaap:Liabilities | $106.8M | 2025-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 22 | assets | us-gaap:Assets | $1.2B | 2023-12-31 | 2025-02-28 | 10-K | filing · viewer · series |
| 23 | assets | us-gaap:Assets | $1.4B | 2022-12-31 | 2024-02-28 | 10-K | filing · viewer · series |
| 24 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 31,230,632 | 2026-02-23 | 2026-02-27 | 10-K | filing · viewer · series |
| 25 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 30,829,454 | 2025-02-24 | 2025-02-28 | 10-K | filing · viewer · series |
| 26 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 27,515,293 | 2026-07-27 | 2026-07-30 | 10-Q | filing · viewer · series |
| 27 | net income | us-gaap:NetIncomeLoss | -$42.7M | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 28 | current assets | us-gaap:AssetsCurrent | $353.6M | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 29 | current liabilities | us-gaap:LiabilitiesCurrent | $72.9M | 2024-12-31 | 2026-02-27 | 10-K | filing · viewer · series |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$16.7M | 2026-06-30 | 2026-07-30 | 10-Q | filing · viewer · series |
| 31 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $7.1M | 2026-03-31 | 2026-05-01 | 10-Q | filing · viewer · series |
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$23.5M | 2025-09-30 | 2025-11-07 | 10-Q | filing · viewer · series |
| 33 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$34.6M | 2025-06-30 | 2026-07-30 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 65.1 is 5.1 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
